

Market Snapshot (Updated at 8AM)

Indian Indices	Close	Net Chng.	Chng. (%)
Sensex	59667.60	410.28	0.68
Nifty	17748.60	106.50	0.60

Global Indices	Close	Net Chng.	Chng. (%)
DOW JONES	34299.99	569.38	1.63
NASDAQ COM.	14546.68	423.29	2.83
FTSE 100	7028.10	35.30	0.50
CAC 40	6506.50	144.41	2.17
DAX	15248.56	325.32	2.09
NIKKEI 225	29399.19	787.08	2.61
SHANGHAI	3552.02	48.46	1.35
HANG SENG	24231.45	233.68	0.95

Currency	Close	Net Chng.	Chng. (%)
USD / INR	74.05	0.21	0.28
USD / EUR	1.17	0.00	0.03
USD / GBP	1.35	0.00	0.09
USD / JPY	111.56	0.13	0.12

Precious Metals	Close	Net Chng.	Chng. (%)
Gold (USD)	1737.06	2.95	0.17
Silver	22.52	0.05	0.21

Energy	Close	Net Chng.	Chng. (%)
NYMEX Crude	74.44	0.85	1.13
Brent Crude	78.20	0.89	1.13
Natural Gas	5.84	0.04	0.75

Bond	Close	Net Chng.	Chng. (%)
10 Yrs G-Sec	6.23	0.02	0.32

Indian ADRs	Close	Net Chng.	Chng. (%)
Dr. Reddy's Lab	64.61	0.05	0.08
HDFC Bank	72.01	2.43	3.26
ICICI Bank	18.98	0.87	4.38
Infosys Ltd	22.09	0.81	3.54
Tata Motors	22.07	0.74	3.24
Vedanta Ltd	15.21	0.01	0.07
Wipro	8.83	0.32	3.50

Institutional Flow (In Crore) 28-09-2021

Institution	Purchase	Sale	Net
FII	8825.85	10783.55	1957.70
DII	7926.05	7764.60	161.45

Key Contents

- ⇒ [Market Outlook/Recommendation](#)
- ⇒ [Today's Highlights](#)
- ⇒ [Global News, Views and Updates](#)
- ⇒ [Links to important News highlight](#)

Top News for Today

- **HDFC Asset Management Company:** Promoter Standard Life Investment seeks up to \$411 million from HDFC AMC share sale, according to terms of the deal. The promoter is offering 1.06 crore shares in HDFC AMC in an accelerated placement. The floor price has been fixed at Rs 2,870, which is at a discount of 6.68% to Tuesday's closing price.
- **Mahindra & Mahindra:** The company is weighing options to raise funds for its Automobili Pininfarina unit as it seeks to bring a delayed \$2.2 million electric hypercar into production, according to a Bloomberg report.
- **Lupin:** The company has launched Droxidopa Capsules in the United States. Droxidopa Capsules is a generic equivalent of Northera Capsules of Lundbeck NA Ltd., indicated for the treatment of orthostatic dizziness and light-headedness in adult patients.
- **Future Group stocks:** The NCLT, Mumbai bench has passed an order allowing the group to hold meetings of shareholders and creditors to seek approval for the scheme of arrangement. The scheme has been proposed between 20 Future Group entities, including 6 listed companies, with Reliance Retail Ventures and Reliance Retail and Fashion Lifestyle. The NCLT has also rejected the intervention application filed by Amazon.
- **Bharti Airtel:** CRISIL Ratings has upgraded its long-term rating on the bank facilities and debt programme of Bharti Airtel to AA+/Stable from AA/Stable and has reaffirmed the A1+ rating on the commercial paper programme.
- **Allcargo Logistics:** Allcargo Belgium NV, a wholly owned subsidiary of the company, has appointed Jefferies Financial as investment banker to evaluate fund raising opportunities for private equity and strategic investment in ECU Worldwide.

Events of the Day

- **AGM:** Vodafone Idea, Indian Railway Catering, Mphasis, Container Corp., Engineers India, Birla Corp, Emami, Dalmia Bharat, Max Healthcare Institute, RailTel Corp, NHPC, Cochin Shipyard, MOIL, Future Consumer, Zee Media Corp., Zee Learn, Ujjivan Financial, Religare Enterprises,
- **Gokaldas Exports:** To meet HDFC Mutual Fund on September 29.
- **Nuvoco Vistas Corporation:** To meet Torq Capital Management on September 29.

Market in Detailed (Updated at 8AM)

Indian Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	59667.60	410.28	0.68	1.12	6.31	13.55	57.13
Nifty	17748.60	106.50	0.60	1.06	6.25	12.70	58.15
BSE M Cap	25015.73	180.10	0.71	0.90	7.57	10.97	70.21
BSE S Cap	27814.98	173.21	0.62	1.04	5.82	10.85	87.17
Nifty MC 100	29951.30	201.15	0.67	1.73	8.11	11.34	76.46
BSE Auto	24091.35	113.60	0.47	5.30	9.15	1.47	34.47
BSE Capgoods	26132.88	70.52	0.27	0.95	6.79	14.23	90.77
BSE FMCG	14969.68	2.65	0.02	2.21	4.34	10.31	37.38
BSE Metal	19872.70	185.88	0.94	1.47	0.31	6.35	134.71
BSE Oil&Gas	18149.60	258.67	1.45	3.88	9.57	11.64	45.44
BSE Healthcare	25786.52	119.91	0.46	1.88	0.31	0.93	30.82
BSE Power	3074.41	45.08	1.49	1.81	8.95	10.56	86.08
BSE Realty	3993.26	124.48	3.02	19.53	32.35	45.08	137.47
BSE ConsDur	40836.43	193.93	0.48	0.96	13.09	15.09	71.10
BSE Bank	43388.12	195.59	0.45	1.76	7.19	9.59	78.46
BSE IT	34545.05	698.80	1.98	1.91	1.74	15.63	73.32

LME	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1737.06	2.95	0.17	1.76	4.44	1.38	8.49
Silver(\$/Ounce)	22.50	0.04	0.20	0.87	6.35	12.70	6.98
Aluminium	2926.00	61.02	2.13	3.57	9.37	18.35	67.82
Copper	9281.10	91.40	0.98	3.32	1.51	0.86	41.49
Zinc	3067.50	12.00	0.39	3.70	2.57	6.13	26.68
Lead	2191.75	8.95	0.41	2.74	10.35	2.59	20.89

Currency	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.05	0.21	0.28	0.59	1.06	0.19	0.36
USD Index	93.72	0.04	0.04	0.28	1.12	1.82	0.18
YUAN	6.47	0.01	0.15	0.12	0.05	0.10	5.35
GBP	1.35	0.00	0.04	0.59	1.58	2.12	5.28
EUR	1.17	0.00	0.03	0.01	0.94	1.77	0.49
YEN	111.56	0.05	0.04	1.59	1.46	0.91	5.28

Agro Commodities	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	198.60	4.95	2.56	8.32	3.33	20.04	70.84
Cotton	100.20	0.17	0.17	10.27	5.65	14.41	52.79
Sugar	19.84	0.16	0.81	0.46	4.06	11.02	56.34
Wheat	710.25	3.50	0.50	0.60	3.07	8.69	23.10
Soybean	1275.50	1.50	0.12	0.57	3.61	2.82	34.62

Global Indices	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34299.99	569.38	1.63	1.12	3.26	0.02	24.94
Nasdaq	14546.68	423.29	2.83	1.35	3.85	0.13	31.23
S&P 500	4352.63	90.48	2.04	0.04	3.48	1.42	30.50
FTSE100	7028.10	35.30	0.50	0.67	1.68	0.84	19.17
CAC40	6506.50	144.41	2.17	0.71	2.63	0.93	34.65
DAX	15248.56	325.32	2.09	0.65	3.81	2.82	18.89
Mexico IPC	50925.52	673.01	1.30	0.19	2.86	1.17	37.14
Brazil Bovespa	110123.9	3459.10	3.05	0.11	8.75	13.51	17.68
Russian RTS	1785.05	19.80	1.12	4.33	7.26	8.84	54.46
Japan Nikkei	29399.19	787.08	2.61	1.48	6.35	2.03	24.89
Hang Seng	24231.45	233.68	0.95	0.19	4.49	16.30	4.26
Taiwan Index	16894.65	287.32	1.67	0.19	1.84	4.00	35.50
Shanghai Comp	3552.02	48.46	1.35	2.06	0.90	0.54	10.22
KOSPI	3038.94	58.24	1.88	3.21	3.01	7.52	30.58
Malaysia KLCI	1533.89	13.07	0.84	0.31	3.55	0.94	1.98
Jakarta Comp	6125.57	12.25	0.20	0.28	1.39	2.96	25.54
Philippine SE	6775.32	110.04	1.60	1.67	0.17	2.61	15.98
Thai Exch	1616.50	3.52	0.22	0.84	0.33	1.58	28.57

Freight	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	4962.00	245.00	5.19	12.52	17.17	45.17	199.28
Baltic Dirty	618.00	2.00	0.32	1.81	2.32	2.15	42.07
SG Dubai HY	2.06	NA	NA	NA	NA	NA	NA

Energy Markets	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	74.44	0.85	1.13	3.06	8.29	2.00	89.46
BRENT Crude	78.20	0.89	1.13	2.64	9.07	7.30	75.38
Natural Gas	5.84	0.04	0.75	20.21	31.62	60.02	101.80

Bond Markets	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.54	0.00	0.23	18.48	17.90	4.84	137.24
UK	0.99	0.04	4.41	23.17	71.97	37.67	392.08
Brazil	4.31	0.09	2.23	8.17	11.44	16.73	9.99
Japan	0.07	0.01	14.12	87.18	170.37	17.74	329.41
Australia	1.50	0.02	1.01	19.12	25.63	2.80	92.16
India	6.23	0.02	0.32	1.45	0.42	2.86	2.84
Switzerland	0.14	0.01	4.90	43.33	60.23	31.31	72.47
Germany	0.20	0.02	10.76	37.22	52.96	4.74	62.31

Taking global cues, the Nifty is expected to open negative around 17650 and likely to remain range-bound in the price band of 17600-17800.

The Nifty previous session ended 0.60% down at 17748.60. It opened on a positive note and got sold off from day's high towards finishing off on a weaker note. Ending the day with a huge Hanging Man candle implies weakness. However, critical support placed around 17600 is still intact. Candle pattern suggests range-bound oscillation in the price band of 17600-17800. We prefer buy on dips as long as critical support placed around 17600 remains intact. Higher resistance is placed around 17850 levels.

On the Nifty hourly chart, oversold leading indicators suggesting the Benchmark Index is likely to oscillate with a positive bias in the price band of 17600-17800.

Nifty patterns on multiple periods suggest; it finished off the day on a weaker note. Hence, range bound oscillation in the price band of 17600-17800 is the most likely scenario.

The Bank Nifty previous session ended 0.59% down at 37945.00. It might get into the trading range of 37300-38400.

Nifty Crucial Supports & Resistances-

Supports- 17600, 17550 Resistances- 17800, 17850

Open Positional Calls-

T+14 Sell-

| Futures Segment | JSW STEEL OCT Fut @ 666-670, TGT- 630, Closing SL- above 690

T+2 Buy

| Cash Segment | LUPIN @ 936-935, TGT- 955, SL- closing below 925

T+3 Buy

| Cash Segment | BPCL @ 426-425, TGT- 435, SL- closing below 420

T+3 Buy

| Cash Segment | SIEMENS @ 2105-2100, TGT- 2160, SL- closing below 2070

T+2 BUY

| Cash Segment | L&T FH @ 89, TGT- 93, SL- closing below 87

T+3 BUY

| Cash Segment | INDIGO @ 2000-1990, TGT- 2050, SL- closing below 1970

BTST

| Cash Segment | MARICO @ 551-550, TGT- 560, SL- closing below 545

BTST

| Cash Segment | PVR @ 1580-1575, TGT- 1605, SL- closing below 1560

BTST

| Cash Segment | IDFC @ 54.50-54, TGT- 56, SL- closing below 53

BTST

| Cash Segment | SUN PHARMA @ 782-780, TGT- 796, SL- closing below 772

- **HDFC Asset Management Company:** Promoter Standard Life Investment seeks up to \$411 million from HDFC AMC share sale, according to terms of the deal. The promoter is offering 1.06 crore shares in HDFC AMC in an accelerated placement. The floor price has been fixed at Rs 2,870, which is at a discount of 6.68% to Tuesday's closing price.
- **Mahindra & Mahindra:** The company is weighing options to raise funds for its Automobili Pininfarina unit as it seeks to bring a delayed \$2.2 million electric hypercar into production, according to a Bloomberg report.
- **Lupin:** The company has launched Droxidopa Capsules in the United States. Droxidopa Capsules is a generic equivalent of Northera Capsules of Lundbeck NA Ltd., indicated for the treatment of orthostatic dizziness and light-headedness in adult patients.
- **Future Group stocks:** The NCLT, Mumbai bench has passed an order allowing the group to hold meetings of shareholders and creditors to seek approval for the scheme of arrangement. The scheme has been proposed between 20 Future Group entities, including 6 listed companies, with Reliance Retail Ventures and Reliance Retail and Fashion Lifestyle. The NCLT has also rejected the intervention application filed by Amazon.
- **Bharti Airtel:** CRISIL Ratings has upgraded its long-term rating on the bank facilities and debt programme of Bharti Airtel to AA+/Stable from AA/Stable and has reaffirmed the A1+ rating on the commercial paper programme.
- **Allcargo Logistics:** Allcargo Belgium NV, a wholly owned subsidiary of the company, has appointed Jefferies Financial as investment banker to evaluate fund raising opportunities for private equity and strategic investment in ECU Worldwide.

Stocks Decline as Yields Stoke Inflation Worries

Asia stocks fell Wednesday after U.S. stocks saw their worst day since May and bond yields spiked on concerns about inflation. Treasuries added to a decline. MSCI Inc.'s gauge of Asian stocks dropped more than 1% and is headed for its first quarterly slide in six. Japan fell more than 2% and Hong Kong and China opened weaker. U.S. futures fluctuated after the S&P 500 closed 2% lower the most since May with concerns over the debt-ceiling impasse in Washington adding to investor angst. The Nasdaq 100 tumbled the most since March as technology shares fared worse than economically sensitive stocks amid rising Treasury yields. The 10-year Treasury yield edged higher. Earlier, the yield on the 30-year note jumped almost 10 basis points. WTI crude retreated toward \$74 a barrel. Brent crude pulled back from a three-year high above \$80 a barrel. Gold was steady after declining. The dollar held gains.

Singapore Cases at Record; Japan to Lift Emergency

Covid-19 infections rose to a record in Singapore, where the increased spread of the virus despite a high vaccination rate is sowing a rare disquiet in the ruling party. In Japan, authorities are lifting a state of emergency at the end of the month as cases drop. Australia plans to withdraw temporary payments for those who have lost work once vaccine thresholds are met. A travel warning for Hong Kong was raised in error on Monday, the U.S. Centers for Disease Control and Prevention said, adding the city still has a low level of the disease. Pfizer Inc. and BioNTech SE came a step closer to bringing their vaccine to school-age children in the U.S.

FDA Leans Toward Authorizing Moderna Booster at a Half Dose

The U.S. Food and Drug Administration is leaning toward authorizing half-dose booster shots of the Moderna Inc. coronavirus vaccine, satisfied that it's effective in shoring up protection, people familiar with the matter said. The authorization would set the stage to further widen the U.S. booster campaign after earlier authorization of the Pfizer Inc.-BioNTech SE shot. About 170 million fully vaccinated people in the U.S. received the Moderna or Pfizer shots, or 92% of the total inoculated so far. The people spoke on the condition of anonymity, before a potential announcement. It's not clear when an announcement will come.

Auto / Auto Ancillaries

[Maruti joins hands with Tata Institute of Social Sciences to offer course in automotive retail](#)

[Maruti eyes better output in October on improved chip supplies](#)

[Jaguar Land Rover commences bookings for I-PACE Black in India](#)

[Tata Motors rolls out 1,00,000th unit of Altroz from Pune plant](#)

[Toyota to hike vehicle prices by up to 2 pc from Oct 1 to offset rise in input costs](#)

[Mahindra is said to weigh electric supercar unit funding options](#)

Banking & Finance

[Soiled notes taking more space than usable ones, banks tell RBI](#)

[Suryoday Bank decides to shut down own ATMs, the first domestic lender to do so](#)

[UPI transaction value doubled to ₹6.06 lakh crore in July](#)

[Indian Bank onboarded as partner bank for offline-online collection of treasury](#)

[Banks, big tech companies, fintech can collaborate to further financial services: Standard Chartered Bank MD Zarin Daruwala](#)

[Star Housing Finance's loan book hits Rs 100 cr so far this fiscal](#)

[Fintech can help check digital frauds, says RBI Deputy Governor Sankar](#)

[FinTech regulation should be more entity-based than activity-based: RBI deputy governor](#)

[Data privacy should not be compromised in using fintech: FM](#)

[DHFL lenders set to mark ₹37,400 crore recovery this week, the biggest among NPAs this fiscal](#)

Oil & Gas

[Oil will be world's No. 1 energy source for decades: OPEC](#)

[Petrol price hiked for first time in 2 months as diesel continues to surge](#)

Metals/Mining/Power

[NGT refuses to vacate order prohibiting mining operations in Chittorgarh](#)

[NFRA finds errors in KIOCL's financial statements for 2019-20 period](#)

[KKR-backed renewable InvIT raises ₹460 crore from AIMCo and other investors](#)

IT/Telecom/Media

[Crisil upgrades long-term rating on Airtel's bank loans, debt programme to AA+/Stable](#)

[Govt may miss Jan-Mar 2022 auction timeline, unless Trai gives pricing recommendations by November](#)

FMCG/Retail/Textile/Food

[Sarda Mines top bidder for Kwaliti Dairy](#)

[Only manufacturing firms registered in India to be eligible under Rs 10,683-cr PLI scheme for textiles sector](#)

[UBL may have to take on debt for CCI's Rs 752 crore penalty](#)

[Future gets NCLT go-ahead to conduct shareholders meeting for deal with Reliance: Sources](#)

[Amazon launches sort centre managed entirely by under-represented cohorts](#)

[NCLT allows Kishore Biyani-owned company to convey shareholders meet for deal with Reliance Retail](#)

[Le Marche to expand dark stores, online verticals: CEO Amit Dutta](#)

Infrastructure/Cement/Real Estate

[67.1% believe AI will be frequently used in Indian real estate: Survey](#)

[Triveni Engineering bets big on ethanol blending, to invest Rs 350 crore to increase distillation capacity](#)

Hospitality/Aviation/Logistics

[Hospitality sector should do well in the second quarter of this year, occupancy levels going up month on month: Puneet Chhatwal, MD and CEO, IHCL](#)

[Wyndham to open newly built Ramada Plaza hotel during summer 2022](#)

[Air India selloff entering last lap, bids may be opened today](#)

[IndiGo to provide domestic connections to American Airlines passengers coming to India](#)

[American Airlines, IndiGo sign codeshare agreement](#)

[In a first, flight crew, air traffic controllers to be tested for drugs like cannabis, cocaine](#)

[Air India gets ready to check out, adds up leave encashment liability](#)

[Winning bid for Air India could be announced by October 15, reports say](#)

Pharma/Fertilizers/Healthcare/Chemical

[US-based PE fund CVC Cap leads race to buy Saijan India](#)

[Anupam Rasayan signs Rs 145-crore letter of intent with European customers to supply active ingredient](#)

[Sanofi drops plans for messenger RNA vaccine against virus](#)

[Working with WHO to resolve issues: Bharat Biotech on Covaxin delay](#)

[Government allows Serum Institute to enrol 7-11 year olds in COVID-19 vaccine trial](#)

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com | Website: www.smifs.com